In September 2023, The US Food and Drug Administration has approved Krystal Biotech’s Investigational New Drug (IND) ...

The Alpha-1 Foundation (A1F) is proud to commemorate its 30th anniversary of supporting patients with Alpha-1 Antitrypsin ...

CONCLUSIONS These data support previous findings that deficiency of α 1-AT is not associated with more severe pulmonary disease in cystic fibrosis and may be associated with milder lung disease.

A rare lung condition has left the 41-year-old, who lives in Halcombe in the Manawatū district, relying on an oxygen tank to ...

Alpha-1 Antitrypsin Deficiency (Alpha-1) is a rare genetic (inherited) condition— passed from parents to their children through their genes. Alpha-1 may result in serious lung disease in adults ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The discontinued program, dubbed NTLA-3001, targets a rare lung disease known as alpha-1 antitrypsin deficiency. Intellia had begun a Phase 1/2 clinical trial testing the therapy in August. Alongside ...

The discontinued program, dubbed NTLA-3001, targets a rare lung disease known as alpha-1 antitrypsin deficiency. Intellia had begun a Phase 1/2 clinical trial testing the therapy in August.

Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive EMA opinion on European Orphan Designation Application; European Commission expected to issue final ...

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...